CHRISTINA DAVIDIAN: Open Payments
NPI 1356920219 · BURBANK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$815 in 28 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $815
Food & beverage: $815
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 9 | $241 |
| Janssen Biotech, Inc. | 3 | $201 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $150 |
| ABBVIE INC. | 4 | $109 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| GENZYME CORPORATION | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| VIVUS LLC | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
Products named: IBSRELA, TREMFYA, XIFAXAN, CREON, DUPIXENT, SKYRIZI, RINVOQ, IQIRVO.
Industry payments across CA — which companies pay providers there.
